Our findings are in line with those of Davies et al., who reported that a higher XBP1s/u ratio was associated with poor survival, absence of estrogen and progesterone receptors, and grade 3 tumors in breast cancer patients undergoing endocrine therapy in the United States.22 This evidence concerns the gene PGR and breast carcinoma.